Evidence map›Paper›PMID 42400626›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

PET imaging of atherosclerotic plaques using the stabilin-2-targeted tracer

Dilibire Adili, Dongsheng Zhang, Guangfa Wang, Haocheng Jin, Ke Sun, Shanshan Zhao, Junru Wu, Chen Su, Hongcheng Shi, Zan Li and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dilibire Adili *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Dongsheng Zhang *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Guangfa Wang *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Haocheng JinDepartment of Sports Medicine & Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Ke SunDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Shanshan ZhaoDepartment of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Junru WuClinical Research Center, Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China.
Chen SuDepartment of Ultrasound Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. shi.hongcheng@zs-hospital.sh.cn.
Zan LiDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. lizan0427@zju.edu.cn.
Xinhui SuDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. suxinhui@zju.edu.cn.ORCID http://orcid.org/0000-0002-4782-3982

Funding

National High Performance Medical Device Innovation Center Innovation Fund NMED2024CX-01-002National Key Research and Development Program of China 2023YFF0716000, 2024YFC2419800National Natural Science Foundation of China 82472013,82071965Science and Technology Department of the State Administration of Traditional Chinese Medicine and the Zhejiang Provincial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-24025Zhejiang Province Vanguard Plan Project 2025C01111
6 · The paper itself

Abstract

purposeElevated Stabilin-2 (STAB2) expression in macrophages within atherosclerotic plaques offers a promising molecular target for imaging vascular inflammation. The S2P peptide specifically binds STAB2. This study aims to evaluate the feasibility of using the STAB2-targeted

methodsStab2 expression was validated via single-cell RNA sequencing of Ldlr

resultsScRNA-seq analysis identified Stab2 as a macrophage-specific marker in atherosclerosis plaque. In vivo micro-PET/CT quantification revealed disease duration-dependent uptake (1.41 ± 0.31 ID%/g at 3 weeks vs. 2.17 ± 0.19 ID%/g at 12 weeks, P < 0.0001), which positively correlated with histological plaque burden.

conclusionThis study introduces a novel STAB2-targeted PET probe (

Indexed as

Atherosclerotic plaquesMacrophage-specific PET tracerPET imagingStabilin-2.

Identifiers

PMID42400626

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.